Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from SPROUT randomised control trial
Br J Dermatol 2025;193:1120–1127 Doi: 10.1093/bjd/ljaf305
Paller et al. evaluated the long-term efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis through the 52-week Phase III SPROUT trial. The study assessed whether clinical responses were sustained after the placebo-controlled period and whether outcomes differed between treatment sequences.